Murata, Koichi http://orcid.org/0000-0002-7896-3937
Hashimoto, Motomu http://orcid.org/0000-0002-9241-060X
Yamamoto, Wataru http://orcid.org/0000-0002-0810-4221
Son, Yonsu http://orcid.org/0000-0001-7244-7715
Amuro, Hideki http://orcid.org/0000-0002-7299-2884
Nagai, Koji http://orcid.org/0000-0002-3183-4193
Takeuchi, Tohru http://orcid.org/0000-0002-0065-929X
Katayama, Masaki http://orcid.org/0000-0002-0773-7238
Maeda, Yuichi http://orcid.org/0000-0002-6831-8205
Ebina, Kosuke http://orcid.org/0000-0002-2426-1024
Hara, Ryota http://orcid.org/0000-0001-8000-3196
Jinno, Sadao http://orcid.org/0000-0003-3021-183X
Onishi, Akira http://orcid.org/0000-0002-3120-1273
Murakami, Kosaku http://orcid.org/0000-0001-5981-4648
Tanaka, Masao http://orcid.org/0000-0002-8942-2933
Ito, Hiromu http://orcid.org/0000-0002-1827-382X
Mimori, Tsuneyo http://orcid.org/0000-0003-0016-2053
Matsuda, Shuichi http://orcid.org/0000-0003-0802-1255
Funding for this research was provided by:
Chugai Pharmaceutical
Eisai
Janssen Pharmaceuticals
Ono Pharmaceutical
Sanofi
Article History
Received: 16 July 2019
Accepted: 10 October 2019
First Online: 16 October 2019
Compliance with ethical standards
:
: KMurat received a speaking fee and/or consulting fee from Eisai Co., Ltd. MH received a research grant and/or speaker fee from Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, and Bristol-Myers Squibb. TT is affiliated with a department that is financially supported by six pharmaceutical companies (Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co. Ltd, AYUMI Pharmaceutical Co., Astellas Pharma, Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited). KN received a research grant and/or speaker fee from Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Bristol-Myers Squibb, Eli Lily, Pfizer Inc, Janssen Pharmaceutical K.K., UCB Japan Co. Ltd, and Asahi Kasei Pharma Corporation. TT received a research grant from Chugai Pharmaceutical Co. Ltd, and a speaker fee from Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb, Eli Lily, Pfizer Inc, Janssen Pharmaceutical K.K., UCB Japan Co. Ltd, Astellas Pharma, and Asahi Kasei Pharma Corporation. YM received a research grant and/or speaker fee from Eli Lily, Chugai Pharmaceutical Co. Ltd., Pfizer Inc, Bristol-Myers Squibb and Mitsubishi Tanabe Pharma Corporation. KE received a research grant and/or speaker fee from Asahi Kasei Corporation, Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Taisho-toyama, and UCB Japan Co. Ltd. SJ received a research grant and/or speaker fee from Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Asahi Kasei Pharma Corporation, Eli Lilly and Company, and AbbVie GK. KMurak has received speaking fees, and/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co. Ltd, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc. M.T. has received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Taisho Pharma Co., Ltd, and Takeda Pharmaceutical Company Limited,. H.I. has received a research grant and/or speaker fee from Bristol-Myers Squibb, Astellas Pharma Inc., Asahi Kasei Pharma Corporation, and Kyocera Medical Co. TM has received research grants and/or speakers’ fees from Astellas Pharma Inc., Asahi Kasei Corporation, AYUMI Pharmaceutical Co., Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi S.A. SM has received a research grant and/or speaker fee from Eisai Co., Ltd., Chugai Pharmaceutical Co. Ltd, and Ono Pharmaceutical Co. All other authors have declared no conflicts of interests.
: This observational study was conducted as per the Declaration of Helsinki and was approved by the ethics committees of all seven institutes: Kyoto University (2016-03-24/approved number R053), Osaka University (2015-11-04/approved number 15300), Osaka Medical College (2014-07-14/approved number 1529), Kansai Medical University (2017-11-21/approved number 2014625), Kobe University (2015-03-20/approved number 1738), Nara Medial University (2018-01-23/approved number 1692), and Osaka Red Cross Hospital (2015-09-01/approved number 644).
: The board of Osaka University Hospital Ethical Committee waived the requirement for patients’ informed consent because of the anonymous nature of the data. Written informed consent was obtained from the participants in other institutes.
: No parts of the manuscript were copied from elsewhere.
: Part of the data was presented at the 63rd annual general assembly and scientific meeting of the Japan College of Rheumatology and the 5th annual meeting of Japanese Society of Osteoimmunogy.
: Koichi Murata, Motomu Hashimoto, Wataru Yamamoto, Yonsu Son, Hideki Amuro, Koji Nagai, Tohru Takeuchi, Masaki Katayama, Yuichi Maeda, Kosuke Ebina, Ryota Hara, Sadao Jinno, Akira Onishi, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Tsuneyo Mimori and Shuichi Matsuda. Does a family history of RA influence the clinical presentation and treatment response in RA? ANSWER Cohort—[abstract] In: the 63rd annual general assembly and scientific meeting of the Japan College of Rheumatology; 2019 Apr 15–14; Kyoto, Kyoto, Japan. Abstract nr P3-007. Koichi Murata, Motomu Hashimoto, Wataru Yamamoto, Yonsu Son, Hideki Amuro, Koji Nagai, Tohru Takeuchi, Masaki Katayama, Yuichi Maeda, Kosuke Ebina, Ryota Hara, Sadao Jinno, Akira Onishi, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Tsuneyo Mimori and Shuichi Matsuda. Does a family history of RA influence the clinical presentation and treatment response in RA? ANSWER Cohort—[abstract] In: the 5th annual meeting of Japanese Society of Osteoimmunogy; 2019 June 25–27; Ishigaki, Okinawa, Japan. Abstract nr P2-1.